Skip to main content

Qiagen Logo

GERMANTOWN, Md. & HILDEN, Germany–(BUSINESS WIRE)– QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced it has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for the fast and easy-to-use QIAreach® Anti-SARS-CoV-2 Total Test.

The authorization means QIAGEN can start making its portable antibody testing device available to health-care professionals in the U.S. Each antibody test takes only about 10 minutes to identify whether a person carries antibodies to the SARS-CoV-2 virus as a result of prior infection. Individual test results are read on a digital eHub device that can process up to 32 tests per hour – and will eventually also run the antigen test.

 

{iframe}https://corporate.qiagen.com/newsroom/press-releases/press-release-details/2021/QIAGEN-Receives-U.S.-FDA-Emergency-Use-Authorization-for-Fast-and-Easy-to-Use-Digital-Test-to-Detect-SARS-CoV-2-Coronavirus-Antibodies/default.aspx?cmpid=CCOM_Non_Non_0521_SM_LinkedInorg_PR{/iframe}

Search

You have successfully subscribed to the newsletter

There was an error while trying to send your request. Please try again.

BioHealth Innovation will use the information you provide on this form to be in touch with you and to provide updates and marketing.